nach oben

Archivum Immunologiae et Therapiae Experimentalis

Erschienen in:

01.12.2022 | Review

Special Issue: Novel Diagnostic and Therapeutic Approach Options in Lupus Nephritis

New Treatment Options in Lupus Nephritis

verfasst von: Pauline M. Montigny, Frédéric A. Houssiau

Erschienen in: Archivum Immunologiae et Therapiae Experimentalis | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to report major recent progresses in the treatment of lupus nephritis (LN). Results of controlled randomized trials are discussed in view of the unmet needs in the field. Current treatments of LN are not satisfactory, with a disappointing proportion of 20–30% of patients achieving complete renal response within 6–12 months, and 5–20% developing end-stage kidney disease within ten years. Two drugs (belimumab and voclosporin) have been officially registered by the medical agencies as add on treatment of LN, a first-in-history success after decades of use of non-registered drugs and trial failures. Other targeted therapies (obinutuzumab and anifrolumab) are currently tested in Phase III trials, after interesting results in Phase II studies. Unanswered questions related to the use of these new drugs are discussed. Recent trials have opened new avenues for the treatment of LN which will hopefully reduce the rate of chronic kidney disease.

Vorheriger Artikel CD5L Secreted by Macrophage on Atherosclerosis Progression Based on Lipid Metabolism Induced Inflammatory Damage

Nächster Artikel Study of Plasma Anti-CD26 Autoantibody Levels in a Cohort of Treatment-Naïve Early Arthritis Patients

Banchereau J, Pascual V (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25:383–392. https://doi.org/10.1016/j.immuni.2006.08.010CrossRefPubMed

Blanco P, Palucka AK, Gill M et al (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294:1540–1543. https://doi.org/10.1126/science.1064890CrossRefPubMed

Brunner HI, Abud-Mendoza C, Viola DO et al (2020) Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis 79:1340–1348. https://doi.org/10.1136/annrheumdis-2020-217101CrossRefPubMed

Chan TM (2015) Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol 11:46–61. https://doi.org/10.1038/nrneph.2014.215CrossRefPubMed

Condon MB, Ashby D, Pepper RJ et al (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72:1280–1286. https://doi.org/10.1136/annrheumdis-2012-202844CrossRefPubMed

Costedoat-Chalumeau N, Houssiau FA (2021) Improving medication adherence in patients with lupus nephritis. Kidney Int 99:285–287. https://doi.org/10.1016/j.kint.2020.10.037CrossRefPubMed

Costedoat-Chalumeau N, Amoura Z, Hulot JS et al (2007) Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 66:821–824. https://doi.org/10.1136/ard.2006.067835CrossRefPubMedPubMedCentral

Costedoat-Chalumeau N, Houssiau F, Izmirly P et al (2019) A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther 106:374–382. https://doi.org/10.1002/cpt.1194CrossRefPubMed

Crickx E, Tamirou F, Huscenot T et al (2021) Molecular signatures of kidney antibody-secreting cells in lupus patients with active nephritis upon immunosuppressive therapy. Arthritis Rheumatol 73:1461–1466. https://doi.org/10.1002/art.41703CrossRefPubMed

D’Cruz D, Maksimowicz-McKinnon K, Oates J et al (2019) Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the embrace study. Lupus Sci Med 6:A149–A150. https://doi.org/10.1136/lupus-2019-lsm.200CrossRef

Dall’Era M, Cisternas MG, Smilek DE et al (2015) Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 67:1305–1313. https://doi.org/10.1002/art.39026CrossRefPubMed

Daniel L, Sichez H, Giorgi R et al (2001) Tubular lesions and tubular cell adhesion molecules for the prognosis of lupus nephritis. Kidney Int 60:2215–2221. https://doi.org/10.1046/j.1523-1755.2001.00055.xCrossRefPubMed

Dooley MA, Houssiau F, Aranow C et al (2013) Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22:63–72. https://doi.org/10.1177/0961203312465781CrossRefPubMed

El Hachmi M, Jadoul M, Lefèbvre C et al (2003) Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 12:692–696. https://doi.org/10.1191/0961203303lu444oaCrossRefPubMed

Fanouriakis A, Kostopoulou M, Cheema K et al (2020) 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79:713–723. https://doi.org/10.1136/annrheumdis-2020-216924CrossRefPubMed

Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930. https://doi.org/10.1002/art.30613CrossRefPubMedPubMedCentral

Furie R, Morand EF, Bruce IN et al (2019) Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 1:e208–e219. https://doi.org/10.1016/S2665-9913(19)30076-1CrossRef

Furie R, Rovin BH, Houssiau F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117–1128. https://doi.org/10.1056/NEJMoa2001180CrossRefPubMed

Furie R, Aroca G, Cascino MD et al (2022) B-cell depletion with Obinutuzumab for the treatment of proliferative lupus nephritis: a randomized, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100–107. https://doi.org/10.1136/annrheumdis-2021-220920CrossRefPubMed

Gladman DD, Urowitz MB, Rahman P et al (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30:1955–1959PubMed

Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436–1446. https://doi.org/10.1056/NEJMoa2024816CrossRefPubMed

Houssiau FA, Vasconcelos C, D’Cruz D et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheumatol 46:2121–2131. https://doi.org/10.1002/art.10461CrossRef

Jayne D, Rovin BH, Mysler E et al (2021a) Randomized, controlled, phase 2 trial of type 1 IFN inhibitor anifrolumab in patients with active proliferative lupus nephritis. Ann Rheum Dis 80:592. https://doi.org/10.1136/annrheumdis-2021-eular.1605CrossRef

Jayne DRW, Merkel PA, Schall TJ et al (2021b) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384:599–609. https://doi.org/10.1056/NEJMoa2023386CrossRefPubMed

Liu Z, Zhang H, Liu Z et al (2015) Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162:18–26. https://doi.org/10.7326/M14-1030CrossRefPubMed

Malvar A, Pirruccio P, Alberton V et al (2017) Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 32:1338–1344. https://doi.org/10.1093/ndt/gfv296CrossRefPubMed

Maria NI, Davidson A (2020) Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nat Rev Rheumatol 16:255–267. https://doi.org/10.1038/s41584-020-0401-9CrossRefPubMed

Maroz N, Segal MS (2013) Lupus nephritis and end-stage kidney disease. Am J Med Sci 346:319–323. https://doi.org/10.1097/MAJ.0b013e31827f4ee3CrossRefPubMed

Mejia-Vilet JM, Malvar A, Arazi A et al (2021) The lupus nephritis management renaissance. Kidney Int S0085–2538:00874–00877. https://doi.org/10.1016/j.kint.2021.09.012CrossRef

Morand EF, Furie R, Tanaka Y et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382:211–221. https://doi.org/10.1056/NEJMoa1912196CrossRefPubMed

Navarra SV, Guzmán RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731. https://doi.org/10.1016/S0140-6736(10)61354-2CrossRefPubMed

Pagni F, Galimberti S, Galbiati E et al (2016) Tubulointerstitial lesions in lupus nephritis: international multicentre study in a large cohort of patients with repeat biopsy. Nephrology 21:35–45. https://doi.org/10.1111/nep.12555CrossRefPubMed

Pamfil C, Makowska Z, De Groof A et al (2018) Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis. Ann Rheum Dis 77:1782–1789. https://doi.org/10.1136/annrheumdis-2018-213485CrossRefPubMed

Parodis I, Adamichou C, Aydin S et al (2020) Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology 59:3424–3434. https://doi.org/10.1093/rheumatology/keaa129CrossRefPubMed

Pirson V, Enfrein A, Houssiau FA et al (2021) Absence of renal remission portends poor long-term kidney outcome in lupus nephritis. Lupus Sci Med 8:e000533. https://doi.org/10.1136/lupus-2021-000533CrossRefPubMedPubMedCentral

Pons-Estel GJ, Alarcon GS, McGwin G Jr et al (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheumatol 61:830–839. https://doi.org/10.1002/art.24538CrossRef

Pons-Estel GJ, Serrano R, Plasín MA et al (2011) Epidemiology and management of refractory lupus nephritis. Autoimmun Rev 10:655–663. https://doi.org/10.1016/j.autrev.2011.04.032CrossRefPubMed

Rovin BH, Furie R, Latinis K et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheumatol 64:1215–1226. https://doi.org/10.1002/art.34359CrossRef

Rovin BH, Solomons N, Pendergraft WF 3rd et al (2019) A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95:219–231. https://doi.org/10.1016/j.kint.2018.08.025CrossRefPubMed

Rovin BH, Adler SG, Barratt J et al (2021a) Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100:753–779. https://doi.org/10.1016/j.kint.2021.05.015CrossRefPubMed

Rovin BH, Teng YKO, Ginzler EM et al (2021b) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070–2080. https://doi.org/10.1016/S0140-6736(21)00578-XCrossRefPubMed

Stohl W, Schwarting A, Okada M et al (2017) Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69:1016–1027. https://doi.org/10.1002/art.40049CrossRefPubMedPubMedCentral

Tamirou F, Lauwerys BR, Dall’Era M et al (2015) A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med 2:e000123. https://doi.org/10.1136/lupus-2015-000123CrossRefPubMedPubMedCentral

Ugolini-Lopes MR, Seguro LPC, Castro MXF et al (2017) Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med 4:e000213. https://doi.org/10.1136/lupus-2017-000213CrossRefPubMedPubMedCentral

Wofsy D, Diamond B, Houssiau FA (2015) Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America. Arthritis Rheumatol 67:1144–1146. https://doi.org/10.1002/art.39067CrossRefPubMedPubMedCentral

Zhang F, Bae SC, Bass D et al (2018) A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 77:355–363. https://doi.org/10.1136/annrheumdis-2017-211631CrossRefPubMed

Zickert A, Sundelin B, Svenungsson E et al (2014) Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med 1:e000018. https://doi.org/10.1136/lupus-2014-000018CrossRefPubMedPubMedCentral

Titel: Special Issue: Novel Diagnostic and Therapeutic Approach Options in Lupus Nephritis
New Treatment Options in Lupus Nephritis
verfasst von: Pauline M. Montigny
Frédéric A. Houssiau
Publikationsdatum: 01.12.2022
Verlag: Springer International Publishing
Erschienen in: Archivum Immunologiae et Therapiae Experimentalis / Ausgabe 1/2022
Print ISSN: 0004-069X
Elektronische ISSN: 1661-4917
DOI: https://doi.org/10.1007/s00005-022-00647-8

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Hydroxychloroquine Therapy and Serum Immunoglobulin Levels in Women with IgG Subclass Deficiency and Systemic Lupus Erythematosus, Sjögren Syndrome, and Rheumatoid Arthritis: A Retrospective Study

CD5L Secreted by Macrophage on Atherosclerosis Progression Based on Lipid Metabolism Induced Inflammatory Damage

Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?

Correction to: CD5L Secreted by Macrophage on Atherosclerosis Progression Based on Lipid Metabolism Induced Inflammatory Damage

Monitoring of Soluble Forms of BAFF System (BAFF, APRIL, sR-BAFF, sTACI and sBCMA) in Kidney Transplantation

Interleukin-35 has a Protective Role in Infectious Mononucleosis-Induced Liver Inflammation Probably by Inhibiting CD8+ T Cell Function